Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild type

Phase 2

• Conditions: advanced or recurrent non-small-cell lung cancer

• Registration Number: JPRN-UMIN000008398
• Lead Sponsor: Gunma Uninersity Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-07-11
• Study Completion: 2015-02-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, or drug-induced pneumonitis 2)Cases with past history of administration of HER related agents 3)4) Patients having EGFR mutation (exon 18,19,20,21) 4)Patients with gastrointestinal disorders 5)Patients with active opthalmological disease 6)Patients with spinal cord compression syndrome 7)Patients with symptomatic brain 8)Patients with active severe infections 9)Patients with active cardiac disease 10)Patients with severe clinical symptom 11)Patients active concomitant malignancy 12)Severe psychological disease 13)Pregnant or breast-feeding females or those who declined contraception 14)Inappropriate patients for this study judged by the attending physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified